ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA - A RANDOMIZED STUDY COMPARING CYCLOPHOSPHAMIDE AND TOTAL-BODY IRRADIATION WITH BUSULFAN AND CYCLOPHOSPHAMIDE
Author(s): CLIFT RA, BUCKNER CD, THOMAS ED, BENSINGER WI, BOWDEN R, BRYANT E, DEEG HJ, DONEY KC, FISHER LD, HANSEN JA, MARTIN P, MCDONALD GB, SANDERS JE, SCHOCH G, SINGER J, STORB R, SULLIVAN KM, WITHERSPOON RP, APPELBAUM FR
Source: BLOOD    Volume: 84    Issue: 6    Pages: 2036-2043    Published: SEP 15 1994  
Times Cited: 242     References: 31     
Abstract: A prospective randomized study was conducted comparing two conditioning regimens for the treatment of patients with chronic myeloid leukemia in chronic phase by marrow transplantation from HLA identical siblings. Sixty-nine patients received 60 mg/kg of cyclophosphamide on each of 2 successive days followed by 6 fractions of total body irradiation each of 2.0 Gy (CY-TBI), and 73 patients received 16 mg/kg of busulfan delivered over 4 days followed by 60 mg/kg CY on each of 2 successive days (BU-CY). There was no significant difference between the CY-TBI and the BU-CY groups in the 3-year probabilities of survival (0.80 for both), relapse (0.13 for both), or event-free survival (CY-TBI, 0.68; BU-CY, 0.71) or in speed of engraftment or incidence of venocclusive disease of the liver. The 4-year probabilities of survival and event-free survival for patients transplanted within 1 year of diagnosis were 0.86 and 0.72, respectively, for each group. Significantly more patients in the CY-TBI group experienced major creatinine elevations. There was significantly more acute graft-versus-host disease in the CY-TBI group. Fever days, positive blood cultures, hospitalizations, and inpatient hospital days were significantly more common in the CY-TBI group than in the BU-CY group. In conclusion, the BU-CY regimen was better tolerated than, and associated with survival and relapse probabilities that compare favorably with, the CY-TBI regimen. (C) 1994 by The American Society of Hematology.
Document Type: Article
Language: English
Reprint Address: CLIFT, RA (reprint author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, ROOM 224-A, SEATTLE, WA 98104 USA
Addresses:
1. VET ADM MED CTR, SEATTLE, WA USA
Publisher: W B SAUNDERS CO, INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399
Subject Category: Hematology
IDS Number: PG388
ISSN: 0006-4971
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo